KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Change in Receivables (2016 - 2025)

Resmed (RMD) has disclosed Change in Receivables for 17 consecutive years, with $72.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 7.12% year-over-year to $72.7 million, compared with a TTM value of $88.0 million through Dec 2025, down 39.52%, and an annual FY2025 reading of $76.7 million, down 42.89% over the prior year.
  • Change in Receivables was $72.7 million for Q4 2025 at Resmed, up from -$30.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $89.3 million in Q2 2021 and bottomed at -$48.8 million in Q4 2021.
  • Average Change in Receivables over 5 years is $22.5 million, with a median of $20.1 million recorded in 2021.
  • Peak annual rise in Change in Receivables hit 347.27% in 2024, while the deepest fall reached 457.35% in 2024.
  • Year by year, Change in Receivables stood at -$48.8 million in 2021, then surged by 140.16% to $19.6 million in 2022, then soared by 36.85% to $26.8 million in 2023, then surged by 153.15% to $67.9 million in 2024, then increased by 7.12% to $72.7 million in 2025.
  • Business Quant data shows Change in Receivables for RMD at $72.7 million in Q4 2025, -$30.0 million in Q3 2025, and $5.2 million in Q2 2025.